Martin William Edwards's Insider Trades & SAST Disclosures
Martin William Edwards's most recent trade in Inozyme Pharma Inc was a trade of 28,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 18, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Martin William Edwards.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inozyme Pharma Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | |
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 23,168 | 23,168 | - | - | Common Stock | |
| Inozyme Pharma Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 2,137 | 2,137 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 93.61 per share. | 07 Jun 2023 | 1,682 | 6,116 (0%) | 0% | 93.6 | 157,452 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 169 | 169 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 93.61 per share. | 07 Jun 2023 | 133 | 4,434 (0%) | 0% | 93.6 | 12,450 | Class A common stock |
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 12,535 | 12,535 | - | - | Director Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 5,620 | 5,620 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 34.76 per share. | 08 Jun 2022 | 3,883 | 4,301 (0%) | 0% | 34.8 | 134,973 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 520 | 520 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 34.76 per share. | 08 Jun 2022 | 359 | 418 (0%) | 0% | 34.8 | 12,479 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 99 | 99 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 27.32 per share. | 03 Jan 2022 | 59 | 59 (0%) | 0% | 27.3 | 1,612 | Class A common stock |
| KalVista Pharmaceuticals Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 10,000 | 10,000 | - | - | Director Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | |
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 12,000 | 12,000 | - | - | Director Stock Option (right to buy) | |
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 24,000 | 24,000 | - | - | Stock Option (right to buy Common Stock) | |
| KalVista Pharmaceuticals Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 7,000 | 7,000 | - | - | Director Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2020 | 6,300 | 6,300 | - | - | Stock Option (right to buy) | |
| Inozyme Pharma Inc | Martin William Edwards | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 9,367 | 9,367 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges